APOE4 Converts Brain Pericytes to Fibrotic Cells, Reversible by TGF-β Blockade

The Cell study integrated single-cell transcriptomic datasets into a human brain vascular atlas, revealing APOE4-induced pericyte transformation that promotes scar deposition and amyloid accumulation around vessels. miBrain organoids derived from induced pluripotent stem cells reproduced the same vascular defects, allowing direct testing of interventions without relying solely on animal models. Blocking TGF-β restored pericyte coverage, reduced fibrosis, and cleared perivascular amyloid in both the human tissue platform and aged APOE4 mice, demonstrating that the vascular pathology is not merely downstream of neurodegeneration but an active, targetable process.

This finding reframes APOE4 from a static risk factor into a driver of reversible vascular damage, connecting to prior observations that cerebrovascular dysfunction precedes cognitive decline in APOE4 carriers by years. It also highlights limitations of purely observational human studies by showing functional reversal only after combining transcriptomics, stem-cell models, and in vivo validation. The miBrain platform adds throughput that traditional postmortem or mouse work lacks, though it still requires confirmation in larger, diverse human cohorts.

Next steps include testing TGF-β pathway inhibitors in APOE4-stratified early-phase trials and expanding miBrain vascular modules to screen additional targets. If vascular rescue proves durable, prevention strategies could shift toward early intervention in genetically at-risk individuals well before amyloid plaques form.